Related references
Note: Only part of the references are listed.Is CD25 blockade optimal in kidney transplant patients treated with basiliximab? A target-mediated drug disposition model
Olivier Le Tilly et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)
The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition
Amina Bensalem et al.
CLINICAL PHARMACOKINETICS (2022)
Confounding factors in exposure-response analyses and mitigation strategies for monoclonal antibodies in oncology
Sonoko Kawakatsu et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model
Jurij Aguiar Zdovc et al.
PHARMACEUTICS (2021)
Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review
Antoine Petitcollin et al.
CLINICAL PHARMACOKINETICS (2020)
Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited
Amina Bensalem et al.
CLINICAL PHARMACOKINETICS (2020)
Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications
Amina Bensalem et al.
CLINICAL PHARMACOKINETICS (2020)
Characterizing Exposure-Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
Haiqing Isaac Dai et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Semimechanistic Clearance Models of Oncology Biotherapeutics and Impact of Study Design: Cetuximab as a Case Study
Ana-Marija Grisic et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2020)
Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans
David Ternant et al.
CLINICAL PHARMACOKINETICS (2019)
Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients
Felicien Le Louedec et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: A pilot study
David Ternant et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)
Jean Marc Phelip et al.
DIGESTIVE AND LIVER DISEASE (2019)
Semimechanistically Based Modeling of Pembrolizumab Time-Varying Clearance Using 4 Longitudinal Covariates in Patients With Non-Small Cell Lung Cancer
Hongshan Li et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance
David C. Turner et al.
CLINICAL CANCER RESEARCH (2018)
Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group
Mira Tout et al.
CLINICAL PHARMACOKINETICS (2017)
Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer
Yoann Pointreau et al.
THERAPEUTIC DRUG MONITORING (2016)
Understanding cachexia as a cancer metabolism syndrome
P. E. Porporato
ONCOGENESIS (2016)
Preliminary Evidence on the Diagnostic and Molecular Role of Circulating Soluble EGFR in Non-Small Cell Lung Cancer
Filippo Lococo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Semimechanistic model to characterize nonlinear pharmacokinetics of nimotuzumab in patients with advanced breast cancer
Leyanis Rodriguez-Vera et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
A Tutorial on Target-Mediated Drug Disposition (TMDD) Models
P. Dua et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2015)
Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients
Nicolas Azzopardi et al.
CLINICAL CANCER RESEARCH (2011)
Population Pharmacokinetic Analysis of Panitumumab in Patients With Advanced Solid Tumors
Peiming Ma et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab
Nicolas Ceze et al.
THERAPEUTIC DRUG MONITORING (2009)
Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer
Erick Gamelin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck
Nathanael L. Dirks et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Approximations of the target-mediated drug disposition model and identifiability of model parameters
Leonid Gibiansky et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2008)
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition
DE Mager et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
Share Paper
